Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity.
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Purpose of review The purpose of this review is to emphasize the pivotal role of glucagon-like peptide 1 (GLP-1) in tackling the parallel epidemics of obesity and type 2 diabetes (T2DM).Recent findings GLP-1-based therapies and in particular GLP-1 receptor agonists (GLP-1 RA) have proven to be effective in lowering blood glucose and decreasing weight. GLP-1 RA not only mitigate these significant medical burdens but also result in weight loss and weight loss independent factors that decrease cardiovascular disease (CVD) and microvascular complications of T2DM, such as diabetic nephropathy. GLP-1-based therapies are critical for a patient-centered approach in choosing appropriate pharmacotherapy for T2DM and obesity while also taking into consideration comorbidities, such as cardiovascular and chronic kidney diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After eating, GLP-1 acts on the hypothalamus to suppress appetite, delay gastric emptying, increase glucose-dependent insulin release, decrease glucagon secretion, and increase pancreatic β-cell growth.98”
From Obesity Management in Adults: A Review (2023) · cites this paper as [98]
Citations
Cites
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
Obesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760
Inflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
Finucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., Singh, G. M., Gutierrez, H. R., Lu, Y., Bahalim, A. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62037-5 · Cited by 4,050
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359
Kim, H. J., Park, S. Y., Choi, Y. J., Han, S. J., Lee, K. W., & Kim, D. J. (2013) · Hormone Research in Paediatrics · doi:10.1159/000348848 · Cited by 3,048
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men
Chan, J. M., Rimm, E. B., Colditz, G. A., Stampfer, M. J., & Willett, W. C. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.961 · Cited by 1,808
The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
Yin, M.-J., Yamamoto, Y., & Gaynor, R. B. (1998) · Nature · doi:10.1038/23948 · Cited by 1,590
Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200958200 · Cited by 1,561
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Aguirre, V., Uchida, T., Yenush, L., Davis, R., & White, M. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.9047 · Cited by 1,487
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Aguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m101521200 · Cited by 1,010
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
The Global Burden of Obesity and the Challenges of Prevention
Seidell, J. C., & Halberstadt, J. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000375143 · Cited by 786
Serine Phosphorylation of Insulin Receptor Substrate 1 by Inhibitor κB Kinase Complex
Gao, Z., Hwang, D., Bataille, F., Lefevre, M., York, D., Quon, M. J., & Ye, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209459200 · Cited by 778
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Obesity: Risk factors, complications, and strategies for sustainable long‐term weight management
Fruh, S. M. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12510 · Cited by 709
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
A Molecular Basis for Insulin Resistance
Paz, K., Hemi, R., LeRoith, D., Karasik, A., Elhanany, E., Kanety, H., & Zick, Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.47.29911 · Cited by 549
Leptin-specific patterns of gene expression in white adipose tissue
Soukas, A., Cohen, P., Socci, N. D., & Friedman, J. M. (2000) · Genes & Development · doi:10.1101/gad.14.8.963 · Cited by 516
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464
Perfetti, R. (2000) · Endocrinology · doi:10.1210/en.141.12.4600 · Cited by 442
Verdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434
Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Orskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
Kim, D. D., & Basu, A. (2016) · Value in Health · doi:10.1016/j.jval.2016.02.008 · Cited by 353
Fehmann, H. C. (1992) · Endocrinology · doi:10.1210/en.130.1.159 · Cited by 337
Dore, D. D., Seeger, J. D., & Arnold Chan, K. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 326
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Garg, R., Chen, W., & Pendergrass, M. (2010) · Diabetes Care · doi:10.2337/dc10-0482 · Cited by 322
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Rinaman, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.059 · Cited by 311
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276
Hernández, C., Bogdanov, P., Corraliza, L., García-Ramírez, M., Solà-Adell, C., Arranz, J. A., Arroba, A. I., Valverde, A. M., & Simó, R. (2016) · Diabetes · doi:10.2337/db15-0443 · Cited by 267
Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251
Glucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246
Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13120 · Cited by 245
Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide I-(7–36)-Amide
Komatsu, R., Matsuyama, T., Namba, M., Watanabe, N., Itoh, H., Kono, N., & Tarui, S. (1989) · Diabetes · doi:10.2337/diab.38.7.902 · Cited by 234
Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M. (2010) · Diabetes Care · doi:10.2337/dc09-1203 · Cited by 229
Meier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Glucagon-like peptide containing pathways in the regulation of feeding behaviour
Tang-Christensen, M., Vrang, N., & Larsen, P. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801912 · Cited by 181
The Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0024 · Cited by 178
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Ahrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G., & Leiter, L. A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13353 · Cited by 157
Carr, R. D., Larsen, M. O., Jelic, K., Lindgren, O., Vikman, J., Holst, J. J., Deacon, C. F., & Ahrén, B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2054 · Cited by 154
Type‐2 diabetes: Current understanding and future perspectives
Pandey, A., Chawla, S., & Guchhait, P. (2015) · IUBMB Life · doi:10.1002/iub.1396 · Cited by 147
A cohort study of acute pancreatitis in relation to exenatide use
Dore, D. D., Bloomgren, G. L., Wenten, M., Hoffman, C., Clifford, C. R., Quinn, S. G., Braun, D. K., Noel, R. A., & Seeger, J. D. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01376.x · Cited by 144
Adam, T. C. M., & Westerterp-Plantenga, M. S. (2005) · British Journal of Nutrition · doi:10.1079/bjn20041335 · Cited by 136
(2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-814222 · Cited by 128
Tang-Christensen, M., Vrang, N., & Larsen, P. J. (1998) · Diabetes · doi:10.2337/diabetes.47.4.530 · Cited by 125
Protein Kinase C and Lipid‐Induced Insulin Resistance in Skeletal Muscle
SCHMITZ‐PEIFFER, C. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04272.x · Cited by 122
Structure of the human ghicagon gene
White, J. W., & Saunders, G. F. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.12.4719 · Cited by 118
Gastric Sensorimotor Functions and Hormone Profile in Normal Weight, Overweight, and Obese People
Roque, M. I. V., Camilleri, M., Stephens, D. A., Jensen, M. D., Burton, D. D., Baxter, K. L., & Zinsmeister, A. R. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.10.025 · Cited by 113
The Coming Age of Flavonoids in the Treatment of Diabetic Complications
Caro-Ordieres, T., Marín-Royo, G., Opazo-Ríos, L., Jiménez-Castilla, L., Moreno, J. A., Gómez-Guerrero, C., & Egido, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020346 · Cited by 107
Gastric and intestinal satiation in obese and normal weight healthy people
Meyer‐Gerspach, A. C., Wölnerhanssen, B. K., Beglinger, B., Nessenius, F., Napitupulu, M., Schulte, F. H., Steinert, R. E., & Beglinger, C. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.02.043 · Cited by 106
GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
Mundil, D., Cameron-Vendrig, A., & Husain, M. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441526 · Cited by 104
The Origin and Understanding of the Incretin Concept
Rehfeld, J. F. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00387 · Cited by 102
Zhang, N., Yang, X., Zhu, X., Zhao, B., Huang, T., & Ji, Q. (2017) · Journal of International Medical Research · doi:10.1177/0300060517693178 · Cited by 99
Bentley-Lewis, R., Aguilar, D., Riddle, M. C., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Johnston, P., Køber, L. V., Lawson, F., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.02.002 · Cited by 98
Gastric Sensorimotor Functions and Hormone Profile in Normal Weight, Overweight, and Obese People
Katzka, D. A. (2007) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(08)70028-x · Cited by 91
Feinle, C., Chapman, I. M., Wishart, J. M., & Horowitz, M. (2002) · Peptides · doi:10.1016/s0196-9781(02)00087-6 · Cited by 89
Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., Ørsted, D. D., Nauck, M. A., the LEADER Steering Committee, & on behalf of the LEADER Trial Investigators (2017) · Diabetes Care · doi:10.2337/dc16-2747 · Cited by 87
Ma, J., Pilichiewicz, A. N., Feinle‐Bisset, C., Wishart, J. M., Jones, K. L., Horowitz, M., & Rayner, C. K. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03496.x · Cited by 82
S100 proteins in obesity: liaisons dangereuses
Riuzzi, F., Chiappalupi, S., Arcuri, C., Giambanco, I., Sorci, G., & Donato, R. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03257-4 · Cited by 78
Wenten, M., Gaebler, J. A., Hussein, M., Pelletier, E. M., Smith, D. B., Girase, P., Noel, R. A., Braun, D. K., & Bloomgren, G. L. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03652.x · Cited by 75
Fan, Y., Liu, K., Wang, Q., Ruan, Y., Ye, W., & Zhang, Y. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.05.004 · Cited by 70
Cefalu, W. T., Buse, J. B., Del Prato, S., Home, P. D., LeRoith, D., Nauck, M. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-1395 · Cited by 61
Seimon, R. V., Brennan, I. M., Russo, A., Little, T. J., Jones, K. L., Standfield, S., Wishart, J. M., Horowitz, M., & Feinle-Bisset, C. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00533.2012 · Cited by 60
Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment.
Higgins, V., & Adeli, K. (2017) · PubMed Central · Cited by 58
Shurter, A., Genter, P., Ouyang, D., & Ipp, E. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.03.018 · Cited by 57
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0825-1 · Cited by 52
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 44
β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity
Aulinger, B. A., Vahl, T. P., Wilson-Pérez, H. E., Prigeon, R. L., & D'Alessio, D. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4009 · Cited by 43
The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
Secrest, M. H., Udell, J. A., & Filion, K. B. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.01.009 · Cited by 42
Mari, A., Bagger, J. I., Ferrannini, E., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073154 · Cited by 40
Dorecka, M., Siemianowicz, K., Francuz, T., Garczorz, W., Chyra, A., Klych, A., & Romaniuk, W. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71069-7 · Cited by 36
Che, X., Zhao, R., Xu, H., Liu, X., Zhao, S., & Ma, H. (2019) · Medical Science Monitor · doi:10.12659/msm.918407 · Cited by 35
Protection of exenatide for retinal ganglion cells with different glucose concentrations
Fu, Z., Kuang, H., Hao, M., Gao, X., Liu, Y., & Shao, N. (2012) · Peptides · doi:10.1016/j.peptides.2012.06.006 · Cited by 32
Cited by
Obesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813
Ahrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G., & Leiter, L. A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13353 · Cited by 157
The Coming Age of Flavonoids in the Treatment of Diabetic Complications
Caro-Ordieres, T., Marín-Royo, G., Opazo-Ríos, L., Jiménez-Castilla, L., Moreno, J. A., Gómez-Guerrero, C., & Egido, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020346 · Cited by 107
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Michałowska, J., Miller-Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 68
Costa, I. M., de Almeida, J. D., da Costa, K. M., Jardim, L. F. S., Rosa, M. J. D. S., Pifano, P. P., de Oliveira, R. R., Silva, S. O., Lima, S. D. S., & Godoy, J. T. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n2-022 · Cited by 79
Metadata
- Authors
- Nolen-Doerr, E., Stockman, M.-C., & Rizo, I.
- Affiliations
- Boston University (US)
- Corresponding author
- Stockman, Mary-Catherine
- Rizo, Ivania
- ORCID
- Rizo, Ivania
- Venue
- Current Obesity Reports
- Published
- 2019-05-23
- Volume
- 8
- Issue
- 3
- Pages
- 284-291
- ISSN
- 2162-4968 (ISSN-L)
- OpenAlex
- W2945534172
- Cited by
- 32
- References
- 98
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 2 · 2021: 8 · 2020: 4 · 2019: 2
- FWCI
- 0.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Current Obesity Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, GLP-1 receptor agonists, type 2 diabetes, obesity, weight loss, glycemic control, cardiovascular disease, diabetic nephropathy, microvascular complications, chronic kidney disease, pharmacotherapy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Blood Glucose, Cardiovascular Diseases, Cardiovascular System, Diabetes Mellitus, Type 2, Humans, Obesity, Weight Loss, Renal Insufficiency, Chronic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.